advanced search
MicroMED 2022 ONdrugDelivery Leaderboard

WEARABLES

INTERVIEW
Interview: Developing Wearable Injectors
Liat Shochat discusses her extensive experience in wearable drug delivery device development, covering the various challenges that arise from the inherent complexity of these devices, even with multiple successful wearable devices on the market, as well as the best way to engage with contract development organisations such as EdgeOne Medical.
WEARABLES
DEVICE DESIGN TO ADDRESS USABILITY AND MITIGATE USE-RELATED RISKS – A MEDICAL AFFAIRS AND HUMAN FACTORS PERSPECTIVE
Dr Sylvine Raverdy-Wilson deep dives into the device constituent of drug-device combination product design and shares perspectives through the Use-Related Risk Analysis methodology with a focus on the BD Libertas™ Wearable Injector.
THE PLATFORM PARADOX: DEVICE DEVELOPMENT CHALLENGES WITHIN FAST EVOLVING DRUG DISCOVERY PIPELINES
EXPERT VIEW
Tim Quigg
THE PLATFORM PARADOX: DEVICE DEVELOPMENT CHALLENGES WITHIN FAST EVOLVING DRUG DISCOVERY PIPELINES
Tim Quigg, Mariam Al-Amari and Joel Gresham discuss how to enable high-dose delivery for novel biologics, using ex vivo and in silico approaches to accelerate drug-device development and improve device performance, thus de-risking projects and saving costs.
ADOPTION OF SUSTAINABILITY PRACTICES WITHIN SUBCUTANEOUS DRUG DELIVERY: INDUSTRY INSIGHTS
PHARMA VIEW
Conor O'Neill
GSK
ADOPTION OF SUSTAINABILITY PRACTICES WITHIN SUBCUTANEOUS DRUG DELIVERY: INDUSTRY INSIGHTS
Conor O’Neill (GSK), Duncan Paterson (AstraZeneca) and Dr Monica Adams (GSK) come together to discuss a recent study conducted by the Subcutaneous Drug Development & Delivery Consortium among its member organisations, digging into the pharmaceutical industry’s progress and priorities when it comes to improving the environmental impact of subcutaneous medicines.
AUTOINJECTORS VERSUS ON-BODY SYSTEMS: THE FUTURE OF LARGE-VOLUME DELIVERY
EXPERT VIEW
Dr Alex Vasiev
AUTOINJECTORS VERSUS ON-BODY SYSTEMS: THE FUTURE OF LARGE-VOLUME DELIVERY
Dr Alex Vasiev and Dr Ethan Miller weigh up the benefits and costs of using on-body injectors versus autoinjectors, discussing delivery, design and patient population variability alongside recent advances in on-body injector development.
POWDER TO THE PEOPLE: ACCELERATING ACCESS TO LYOPHILISED THERAPIES
EXPERT VIEW
Kristien De Clercq
POWDER TO THE PEOPLE: ACCELERATING ACCESS TO LYOPHILISED THERAPIES
Kristien De Clercq and Dr Alex Vasiev discuss the challenges and recent advances in drying and reconstitution technologies, as well as how, while dual-chamber primary packaging offers a potential solution for simplifying reconstitution, it remains underused due to usability concerns and a prevailing industry preference for vial-based lyophilisation over alternative drying methods such as spray drying and powder filling.
DIVERGENT DESIGN PHILOSOPHIES IN THE WEARABLE INJECTOR SEGMENT
WEARABLES
Reto Jost
Ypsomed
DIVERGENT DESIGN PHILOSOPHIES IN THE WEARABLE INJECTOR SEGMENT
Reto Jost and Daniel Käser detail how Ypsomed is approaching wearable injector design with YpsoDose and achieving large-volume requirements, consistent dosing and low residual waste, going on to explain how the company’s design choices are integrated with patient-centric features to ensure adherence and comfort.
SYMBIOZE<sup>®</sup> – THE ELECTROMECHANICAL ON-BODY DRUG DELIVERY SYSTEM FOR LARGE-VOLUME IMMUNOTHERAPIES
WEARABLES
Corinne Malica
Nemera
SYMBIOZE® – THE ELECTROMECHANICAL ON-BODY DRUG DELIVERY SYSTEM FOR LARGE-VOLUME IMMUNOTHERAPIES
Corinne Malica and Cécile Gross discuss the challenges involved in developing a wearable device for on-body drug delivery of advanced biologics, with a focus on the immunotherapy sector, and the technical solutions that can overcome them, using Nemera’s Symbioze® as an example.
ON-BODY INJECTORS: A PROMISING SOLUTION TO THE UK’S SYSTEMIC ANTI-CANCER THERAPY CRISIS
WEARABLES
Omar Rahman
Enable Injections
ON-BODY INJECTORS: A PROMISING SOLUTION TO THE UK’S SYSTEMIC ANTI-CANCER THERAPY CRISIS
Omar Rahman, Catherine Loughran and Rachel Senior consider how on-body injectors, such as Enable’s enFuse, can help to reduce the administrative burden on the healthcare system as well as giving patients more autonomy and dignity in managing their disease.
REDEFINING PATIENT-CENTRIC DRUG DELIVERY: A CLOSER LOOK AT VERTIVA<sup>®</sup> ON-BODY DELIVERY SYSTEM
WEARABLES
Anna Allegro
Stevanato Group
REDEFINING PATIENT-CENTRIC DRUG DELIVERY: A CLOSER LOOK AT VERTIVA® ON-BODY DELIVERY SYSTEM
Anna Allegro explores current challenges in wearable injectors and how the next generation of on-body delivery systems, such as Stevanato’s Vertiva® platform, aims to close the gap between technical performance and true patient centricity.
ADVANCING CANCER CARE THROUGH ON-BODY SUBCUTANEOUS INJECTIONS: THE ONCOLOGY COMMUNITY’S PERSPECTIVE
EXPERT VIEW
Dr Greg Moakes
ADVANCING CANCER CARE THROUGH ON-BODY SUBCUTANEOUS INJECTIONS: THE ONCOLOGY COMMUNITY’S PERSPECTIVE
Dr Greg Moakes discusses the role that on-body delivery systems have to play in modernising the delivery of oncology drugs, digging into the survey results of over 200 attendees of the American Society of Clinical Oncology 2025 Global Meeting as to their opinions on the place of this pivotal technology in oncological practice.
VISTA BY TXSPHERE: TRAVERSING THE LIMITATIONS OF SMALL-VOLUME BIOLOGICS
WEARABLES
Dr Chaoyoung Lee
TxSphere
VISTA BY TXSPHERE: TRAVERSING THE LIMITATIONS OF SMALL-VOLUME BIOLOGICS
Dr Chaoyoung Lee and Mike Stout unveil an innovative addition to TxSphere's wearable platform, Vista, designed to improve on efficiency goals, adapt to varied drug formulations and advance beyond the requirements of low-volume drug delivery.
INJECTING DRUGS DIRECTLY INTO THE BODY: HOW ON-BODY DELIVERY SYSTEMS ARE REVOLUTIONISING THERAPY
WEARABLES
Peter Schmidt
ZwickRoell
INJECTING DRUGS DIRECTLY INTO THE BODY: HOW ON-BODY DELIVERY SYSTEMS ARE REVOLUTIONISING THERAPY
Peter Schmidt discusses the advantages of on-body delivery systems and what makes them special, going on to consider the significant role that they are expected to play in the future of injection technology for the pharmaceutical and medical fields, as well as the role that comprehensive testing plays in bringing this technology to patients.
ACCELERATING DEVELOPMENT OF ELECTROMECHANICAL DELIVERY SYSTEMS VIA MODULAR INTEGRATION
WEARABLES
Nicholas Ciccarelli
Kymanox
ACCELERATING DEVELOPMENT OF ELECTROMECHANICAL DELIVERY SYSTEMS VIA MODULAR INTEGRATION
Nicholas Ciccarelli, Andrew King, Dr Marcus Herrmann and Dr Thomas Roschke, discuss the insights gained in the product development process from the recent collaboration between the two companies, with Kymanox managing the overall system integration and Johnson MedTech tackling the specific design of the drive system within the designated product specification.
SAFE AND SKIN-FRIENDLY MANUFACTURING OF MEDICAL WEARABLES WITH ULTRASONIC WELDING
EXPERT VIEW
Michael Boerner
SAFE AND SKIN-FRIENDLY MANUFACTURING OF MEDICAL WEARABLES WITH ULTRASONIC WELDING
Michael Boerner looks at the key factors for designing skin-friendly medical wearables and how to manufacture them safely, automatically and sustainably.
SELF-INJECTION DEVICE MANUFACTURING IN A DYNAMIC WORLD
INDUSTRIALISATION
Philipp Richard
Ypsomed
SELF-INJECTION DEVICE MANUFACTURING IN A DYNAMIC WORLD
Philipp Richard scrutinises the efficient production of self-injection devices in the pharma industry and describes Ypsomed’s own platforms for developing these devices, highlighting the need to be adaptable and resilient to the rapidly evolving world of drug development. He provides valuable insights into the ways in which the flexible manufacture of self-injection devices might be achieved.
THE POWER OF PARTNERSHIP AND CLOSE COLLABORATION FOR FILLING ON-BODY INJECTORS
WEARABLES
Mary Lou Glotzbach
Grand River Aseptic Manufacturing
THE POWER OF PARTNERSHIP AND CLOSE COLLABORATION FOR FILLING ON-BODY INJECTORS
Mary Lou Glotzbach and Dr Greg Moakes consider the implications of the increasing demand for high-volume injections across the drug delivery industry, and how technologies such as wearable injectors are creating novel challenges for the fill-finish process due to the novel containers involved, making the case that it is only through clear communication and close collaboration between partners that these challenges can be met and surmounted.
Product Showcase: CCBIO’S INJECTOR PLATFORM PRODUCTS
INJECTION
Jimmy Fan
CC Bio
Product Showcase: CCBIO’S INJECTOR PLATFORM PRODUCTS
CCBio’s expanding portfolio of self-injection devices reflects the growing importance of at-home administration in driving adherence across a range of therapies. This showcase explores the clinical rationale behind self-injection and details CCBio’s latest innovations, including electronic-assisted devices and Taiwan-based automated assembly.
UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS
SUSTAINABILITY
Stevanato Group
UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS
Stevanato Group examines how semi-reusable, modular designs like its Vertiva 10 mL on-body delivery system can reconcile patient demands for ease of use with growing expectations for sustainability, sharing new UK preference data and lifecycle analysis that reveal significant waste and emissions reductions.
THE RISE OF LARGE-VOLUME SUBCUTANEOUS ADMINISTRATION OF BIOPHARMACEUTICALS, AND DELIVERY IMPLICATIONS
INJECTION
Dr Andreas Schneider
Ypsomed
THE RISE OF LARGE-VOLUME SUBCUTANEOUS ADMINISTRATION OF BIOPHARMACEUTICALS, AND DELIVERY IMPLICATIONS
Andreas Schneider and Jakob Lange consider the SC administration of larger volumes of biopharmaceuticals in the pharma industry and summarise a recent study that reviews clinical-stage and approved IV and SC biopharmaceuticals to provide valuable guidance for new product development, as well as for marketing and commercialisation strategies in the rapidly evolving large-volume SC landscape.
DRUG DELIVERY TRENDS FOR 2025
EXPERT VIEW
Tom Oakley
DRUG DELIVERY TRENDS FOR 2025
Tom Oakley and Alex Vasiev look back at how the trends anticipated for 2024 played out in reality and look forward to four major trends expected to influence the drug delivery industry in 2025.
EMPOWERING PHARMA WITH INNOVATIVE INFUSION TECHNOLOGIES AMID US POLICY CHANGES
INJECTION
Mindy Katz
Eitan Medical
EMPOWERING PHARMA WITH INNOVATIVE INFUSION TECHNOLOGIES AMID US POLICY CHANGES
Mindy Katz and Michael Ratigan outline the implications for pharmaceutical manufacturers of recent US policy changes – and highlight how Eitan Medical’s portfolio of infusion solutions can offer support.
NOVEL SOLUTIONS FOR ULTRA-LARGE-VOLUME WEARABLE AND PORTABLE SUBCUTANEOUS INJECTORS
WEARABLES
Dr Hong-Jun Yeh
MicroMED Co Ltd
NOVEL SOLUTIONS FOR ULTRA-LARGE-VOLUME WEARABLE AND PORTABLE SUBCUTANEOUS INJECTORS
Dr Hong-Jun Yeh, Jiunn-Ru Lai and Tsung-Chieh Cheng discuss the need for novel approaches to the challenge of delivering high volumes of biologics while also addressing patient centricity, and introduce MicroMED’s two innovative gas-powered approaches that leverage micro-electromechanical systems to drive the injection.
SUBCUTANEOUS DRUG DELIVERY: ADAPTING TO HIGH-VISCOSITY, LARGE-VOLUME DEMANDS
INJECTION
Thomas Fontanellaz
Ypsomed
SUBCUTANEOUS DRUG DELIVERY: ADAPTING TO HIGH-VISCOSITY, LARGE-VOLUME DEMANDS
Thomas Fontanellaz, Reto Jost and Andreas Schneider discuss how Ypsomed is addressing the growing need for subcutaneous injections that accommodate higher volumes and viscosities, with innovative self-injection devices designed to enhance patient comfort and adherence.
SPRINGS: THE KEY TO ADVANCED AUTOINJECTOR AND PEN INJECTOR PERFORMANCE
INJECTION
Emilie Aranda
RPK Medical
SPRINGS: THE KEY TO ADVANCED AUTOINJECTOR AND PEN INJECTOR PERFORMANCE
Emilie Aranda and Fernando González discuss the crucial role of spring mechanisms and other metal parts in autoinjectors and pen injectors.
DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS
EXPERT VIEW
Kyle Toole
DEFINING HIGH-VISCOSITY, LARGE-VOLUME DRUG DELIVERY SYSTEMS
Kyle Toole, Blair Hutton and James McLusky discuss the value that mathematical modelling can provide in the early stages of injectable drug delivery device development, especially when coupled with appropriate empirical testing in a laboratory setting.
Top